Cure Alzheimer’s Fund Strengthens Leadership with New Board Appointments

The Cure Alzheimer’s Fund, a nonprofit organization at the forefront of funding research aimed at preventing, slowing, or reversing Alzheimer’s disease, has announced the addition of Christine Villas-Boas and Brittany Bowlen to its Board of Directors. This strategic move underscores the organization's dedication to leveraging diverse expertise and passion in its mission to eradicate Alzheimer’s disease, a condition that affects millions worldwide and poses significant challenges to healthcare systems and families.

Henry McCance, Board Chair and Co-Founder of Cure Alzheimer’s Fund, highlighted the importance of the new appointments, noting the unique perspectives and commitment both individuals bring to the table. Christine Villas-Boas, with her extensive background in finance and philanthropy, and Brittany Bowlen, known for her leadership in strategy and community impact, are expected to play pivotal roles in guiding the organization’s efforts to fund groundbreaking research.

The implications of these appointments extend beyond the organization, offering hope to the millions affected by Alzheimer’s disease. With the global prevalence of Alzheimer’s expected to rise, the need for effective treatments and a cure has never been more urgent. The Cure Alzheimer’s Fund’s approach, focusing on 100% of general donations going directly to research, sets a benchmark for transparency and efficiency in nonprofit operations, further amplified by the expertise of its newly expanded board.

Christine Villas-Boas’s personal connection to the cause, driven by the loss of her mother to Alzheimer’s, and Brittany Bowlen’s proven track record in strategic leadership and community engagement, exemplify the caliber of individuals now steering the organization. Their involvement not only brings fresh energy and ideas but also reinforces the collective resolve to tackle one of the most pressing health challenges of our time.

As the Cure Alzheimer’s Fund continues to grow and evolve, the addition of Villas-Boas and Bowlen to its Board of Directors marks a significant milestone in its journey toward finding a cure for Alzheimer’s disease. Their leadership and dedication are poised to accelerate the organization’s impact, offering new avenues for research and hope for a future free from Alzheimer’s.